
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research PLC has experienced a notable stock increase of approximately 22%, driven by promising developments surrounding its candidate GH001 for the treatment of Treatment-Resistant Depression (TRD), characterized by short clinical duration, rapid and durable efficacy, and favorable safety profiles. The recent lifting of the FDA's clinical hold on GH001 allows the company to advance towards a global Phase 3 program, with analysts projecting a potential market opportunity exceeding $1.4 billion at peak in TRD, in addition to anticipated revenues from other indications. Expectations surrounding GH001's pricing have been adjusted upward, reflecting confidence in its competitive advantages compared to existing treatments, positioning the company for significant financial growth and market penetration.
Bears say
GH Research PLC faces significant risks and uncertainties that contribute to a negative outlook on its stock. Key concerns include potential delays in progressing to Phase III trials due to regulatory challenges, unexpected safety signals, and failures in achieving sufficient efficacy, which could jeopardize the company's ability to commercialize its product candidates GH001 and GH002. Additionally, the absence of revenue generation, the complexities of developing neuropsychiatric treatments, and the competitive landscape further heighten the risks surrounding GH Research's financial stability and market viability.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares